Patents Represented by Attorney Joseph J. Brindisi
-
Patent number: 5464865Abstract: The invention provides novel 5-hydroxy-4-aryl- and 5-hydroxy-4-(arylthio)-2(5H)-furanones of the following structure: ##STR1## wherein R contains from about five to about twenty carbon atoms and is defined herein; X is oxygen, sulfur, SO.sub.2, NH, N(lower alkyl), N(lower acyl), aminocarbonyl, carbonyl, carbonylamino, CH.sub.2 or a carbon-carbon bond; Y is hydrogen, halogen, lower alkyl, nitro, alkylthio, perfluoroalkyl, hydroxy, or lower alkoxy(C.sub.1 -C.sub.8); Z is sulfur or a carbon-carbon bond; and Q is H, an alkyl of from 1-20 carbon atoms, COR', COOR', CONHR', PO(OR')2, PO(OR')R" wherein R' and R" are independently selected from the group consisting of H, an alkyl of from 1-20 carbon atoms, phenyl, and substituted phenyl and prodrugs thereof and pharmaceutically acceptable salts thereof.Type: GrantFiled: December 22, 1993Date of Patent: November 7, 1995Assignee: Ortho Pharmaceutical CorporationInventors: James P. Demers, Richard B. Sulsky
-
Patent number: 5464870Abstract: This invention relates to methods of inhibiting development of leukoplakia or malignant lesions in a patient comprising the step of administering an effective leukoplakia or malignant lesion inhibiting amount of fenretinide to a patient wherein the administration of the fenretinide incurs less significant undesirable side effects than administration of other vitamin A retinoid derivatives.Type: GrantFiled: February 10, 1993Date of Patent: November 7, 1995Assignee: Ortho Pharmaceutical CorporationInventors: Umberto Veronesi, Fausto Chiesa, Alberto Costa
-
Patent number: 5342851Abstract: This invention relates to substituted thiazole derivatives of the following general formula, the substituent groups of which are as defined herein: ##STR1## These compounds are useful as inhibitors of platelet aggregation and inhibitors of adhesion molecules and may be provided in pharmaceutical compositions and in methods of treating reperfusion thrombosis injury in patients.Type: GrantFiled: October 7, 1992Date of Patent: August 30, 1994Assignee: McNeil-PPC, Inc.Inventors: Pauline J. Sanfilippo, Maud Urbanski, John R. Carson, Richard J. Carmosin
-
Patent number: 5330427Abstract: This invention relates to a suppository applicator adapted for administering medicament in a suppository form to a body cavity. More particularly, it relates to a one-piece injection molded article having a main body portion and a flexible chamber whereby the flexible chamber is inverted in use to expel the medicament from the applicator into a body cavity.Type: GrantFiled: March 5, 1993Date of Patent: July 19, 1994Assignee: Ortho Pharmaceutical CorporationInventor: Edward A. Weissenburger
-
Patent number: 5310941Abstract: This invention relates to aminoethylthiophene derivatives and more particularly 2- and 3-aminoethylthiophene derivatives which are useful as antiarrhythmic agents, their methods of use as antiarrhythmic agents, and novel intermediate compounds useful for preparation of the aminoethylthiophene derivatives of the invention.Type: GrantFiled: January 13, 1993Date of Patent: May 10, 1994Assignee: Ortho Pharmaceutical CorporationInventors: Ronald K. Russell, Joseph J. Salata
-
Patent number: 5294621Abstract: This invention relates to thieno tetrahydropyridine and isoquinoline derivative compounds which are useful as antiarrhythmic agents, pharmaceutical compositions comprising such compounds, novel intermediates for their preparation and their methods of use. More particularly these thieno tetrahydropyridine and isoquinoline derivative compounds have been demonstrated to increase the effective refractory period (ERP) of isolated perfused cardiac tissue in vitro.Type: GrantFiled: October 7, 1992Date of Patent: March 15, 1994Assignee: Ortho Pharmaceutical CorporationInventor: Ronald K. Russell
-
Patent number: 5294708Abstract: This invention relates to new heterocyclic derivatives of guanidine and more particularly to such derivatives which have hypoglycemic activity, their methods of use for treating hyperglycemia and novel intermediate compounds for their preparation.Type: GrantFiled: July 20, 1993Date of Patent: March 15, 1994Assignee: McNeilab, Inc.Inventors: Henry J. Breslin, Michael J. Kukla, Chris R. Rasmussen, Robert W. Tuman
-
Patent number: 5290781Abstract: This invention relates to the use of ketanserinol as an ophthalmic therapeutic agent to reduce intraocular pressure and its method of use for treating glaucoma by systemic administration of ketanserinol, it salts, esters or prodrugs to a patient or more particularly, topically administering ketanserinol and salts thereof to the eye of a patient.Type: GrantFiled: January 5, 1993Date of Patent: March 1, 1994Assignee: Iolab CorporationInventors: Ramon L. Espino, Donald G. Musson, Orest Olejnik
-
Patent number: 5268373Abstract: This invention relates to new heterocyclic derivatives of guanidine and more particularly to such derivatives which have hypoglycemic activity, their methods of use for treating hyperglycemia and novel intermediate compounds for their preparation.Type: GrantFiled: July 28, 1992Date of Patent: December 7, 1993Assignee: McNeilab, Inc.Inventors: Henry J. Breslin, Michael J. Kukla, Chris R. Rasmussen, Robert W. Tuman
-
Patent number: 5258525Abstract: The processes provide for the preparation of a [2S-(2.alpha., 3a.beta., 7a.beta.)]-octahydro-lH-indole-2-carboxylic ester from an ester precursor by a stereospecific hydrogenation at a pressure below about 400 psi. In addition, the processes provide for the preparation of [2S-(2.alpha.m 3a.beta., 7a.beta.)]-octahydro-lH-indole-2-carboxylic acid or a ester thereof by the hydrogenation of a (2S)-2-carboxyindoline acid precursor.Type: GrantFiled: March 27, 1991Date of Patent: November 2, 1993Assignee: McNeilab, Inc.Inventors: Cynthia A. Maryanoff, Cynthia L. Fedde, Robin C. Stanzione, Frank J. Villani, Jr.
-
Patent number: 5221742Abstract: The invention relates to a process for the synthesis of compounds of the formula I ##STR1## wherein R.sub.1 -R.sub.5 are as defined herein. The process is a multistep process which comprises acylating a 2-benzoxazolinone with an alkanoic anhydride to form an acylated carbamate, hydrolyzing the carbamate, reacting the resultant aminophenol with haloalkanoyl halide to form a substituted benzoxazine, reacting the benzoxazine with an aldehyde, alkylating the resultant aminomethyl compound with an alkylating agent to form a quaternary ammonium salt, reacting the salt with an alkali metal cyanide to form a nitrile, hydrolyzing the nitrile and reacting the resultant carboxylic acid with hydrazine.The compounds are useful as cardiotonic and vasodilating agents and as inhibitors of phosphodiesterase fraction III and platelet aggregation. In addition, the compounds are active as smooth muscle relaxants and bronchodilators.Type: GrantFiled: December 21, 1990Date of Patent: June 22, 1993Assignee: Ortho Pharmaceutical CorporationInventors: Donald W. Combs, James P. Demers
-
Patent number: 5213566Abstract: This invention relates to a suppository applicator adapted for administering medicament in a suppository form to a body cavity. More particularly, it relates to a onepiece injection molded article having a main body portion and a flexible chamber whereby the flexible chamber is inverted in use to expel the medicament from the applicator into a body cavity.Type: GrantFiled: June 5, 1992Date of Patent: May 25, 1993Assignee: Ortho Pharmaceutical CorporationInventor: Edward A. Weissenburger
-
Patent number: 5208252Abstract: This invention relates to aminoethylthiophene derivatives and more particularly 2-and 3-aminoethylthiophene derivatives which are useful as antiarrhythmic agents, their methods of use as antiarrhythmic agents, and novel intermediate compounds useful for preparation of the aminoethylthiophene derivatives of the invention.Type: GrantFiled: July 24, 1992Date of Patent: May 4, 1993Assignee: Ortho Pharmaceutical CorporationInventors: Ronald K. Russell, Joseph J. Salata
-
Patent number: 5208327Abstract: This invention relates to a novel process for preparing 2-chloro-2'-deoxyadenosine (2-CdA) having the following formula ##STR1## from a compound of the following formula ##STR2## The invention also relates to intermediates which are useful in preparing 2-CdA. The compound 2-CdA is useful as an antileukemic agent, i.e., in treating leukemias, such as hairy cell leukemia.Type: GrantFiled: April 16, 1992Date of Patent: May 4, 1993Assignee: Ortho Pharmaceutical CorporationInventor: Robert H. K. Chen
-
Patent number: 5093133Abstract: An ibuprofen containing hydroalcoholic gel of pH 3.5 to 6.0 for topically treating inflammation or pain comprising an effective amount of ibuprofen; 40 to 60% alcohol, e.g. ethanol or isopropyl alcohol; 0-20% of a non-volatile solvent, e.g. propylene glycol; 2.0 to 5.0% gelling agents, e.g. 2.5% hydroxypropyl cellulose or 4.0% polyacrylic acid polymer; sufficient base, e.g. triethanolamine, to adjust the pH to between 3.5 and 6.0; and water; methods for delivering ibuprofen through the skin to treat inflammation or pain using the hydroalcoholic gel; and use of substantially pure S-ibuprofen to topically treat such inflammation or pain.Type: GrantFiled: January 24, 1990Date of Patent: March 3, 1992Assignee: McNeil-PPC, Inc.Inventors: Stephen J. Wisniewski, Mark Gemborys
-
Patent number: 5075114Abstract: Chewable medicament tablets are made from coated granules of a medicament wherein the coating on said granules comprises a blend of cellulose actate and/or cellulose acetate butyrate and hydroxypropyl cellulose and a process for making such tablets and a method of providing sustained release of medicaments utilizing such coated granules in a tablet.Type: GrantFiled: May 23, 1990Date of Patent: December 24, 1991Assignee: McNeil-PPC, Inc.Inventor: Edward J. Roche
-
Patent number: 5073380Abstract: A pharmaceutical sustained release tablet or tablet layer is formed by making a wet granulation, using povidone (PVP) in water or alcohol-water as the granulating fluid which is mixed with a pharmaceutical active, hydroxyethyl cellulose, a wicking agent e.g. microcrystalline cellulose, then drying and milling the granulation and blending with dry powdered smoothness enhancer, e.g. povidone, erosion promoter, e.g. pregelatinized starch, additional wicking agent, lubricant e.g. magnesium stearate and glidant e.g. silicon dioxide, and compressing the resultant granulation into a tablet with a smooth outer surface, which tablet provides, upon administration, a slow release of the pharmaceutical active.Type: GrantFiled: July 9, 1990Date of Patent: December 17, 1991Assignee: McNeil-PPC, Inc.Inventors: Suresh R. Babu, Robert Glinecke, John L. Murtha, Galen W. Radebaugh
-
Patent number: 5004613Abstract: A pharmaceutical sustained release tablet or tablet layer is formed by making a wet granulation, using povidone (PVP) in water or alcohol-water as the granulating fluid which is mixed with a pharmaceutical active, hydroxyethyl cellulose, a wicking agent e.g. microcrystalline cellulose, then drying and milling the granulation and blending with dry powdered erosion promotor, e.g. pregelantinized starch, additional wicking agent, lubricant e.g. magnesium stearate and glidant e.g. silicon dioxide, and compressing the resultant granulation, which upon administration results in a slow release of the pharmaceutical active.Type: GrantFiled: August 11, 1989Date of Patent: April 2, 1991Assignee: McNeil-PPC, Inc.Inventors: Galen W. Radebaugh, John L. Murtha, Robert Glinecke
-
Patent number: 4992259Abstract: A stable and clear aqueous solution of zinc salt useful as a mouthrinse and a gel dentifrice. In a preferred embodiment the aqueous solution comprises zinc chloride codissolved with a complexing agent of sodium gluconate, in a naturally derived anionic polymer of sodium carboxymethylcellulose. This solution is advantageous because it maintains clarity and chemical stability in temperatures of from about 4.degree. to about 50.degree. C. and may be alcohol-free. The anionic polymer acts as a buffer to provide a solution with a pH in a desirable range of from about 5.7 to about 6.5, which limits astringency and tartness.Type: GrantFiled: January 3, 1990Date of Patent: February 12, 1991Assignee: Johnson & Johnson Consumer Products, Inc.Inventors: Michael T. Schiraldi, Robert K. Denton, Jr.
-
Patent number: 4968509Abstract: An acetaminophen-sustained release tablet or tablet layer is formed by making a wet granulation, using Povidone (PVP) in water or alcohol-water as the granulating fluid which is mixed with acetaminophen, hydroxyethyl cellulose, a wicking agent e.g. microcrystalline cellulose, then drying and milling the granulation and blending with dry powdered erosion promoter, e.g. pregelatinized starch, wicking agent, lubricant e.g. magnesium stearate and glidant e.g. silicon dioxide, and compressing the resultant granulation, which upon administration results in a slow release of the acetaminophen.Type: GrantFiled: January 19, 1989Date of Patent: November 6, 1990Assignee: McNeilab, Inc.Inventors: Galen W. Radebaugh, John L. Murtha, Robert Glinecke